ClinicalTrials.gg
RecruitingNCT06425341Updated Nov 17, 2025

A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in Patients Treated for Chronic Hepatitis B

A Phase 2 interventional study of HRS-5635 Injection and HRS-5635 Injection in Chronic Hepatitis B, sponsored by Fujian Shengdi Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-17.

Sponsored by Fujian Shengdi Pharmaceutical Co., Ltd. (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
369
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 375 studies in Hepatitis B, Chronic with a site in China — 89 open to participants now, 110 under way, 7 of them phase 3. Hepatitis B, Chronic · China.

Planned enrollment
51st of 273
369 · median 120
Started
2024
with 33 others
Phase 2
72 of 375
15 open now
Primary completion
2026-08
later than 33 of 109 live
Registered
288th of 375
by date

Among the 375 studies in Hepatitis B, Chronic with a site in China, this one is the 51st largest by planned enrollment of the 273 interventional ones that give a count, is one of 34 that started in 2024, is one of 72 in phase 2, reaches primary completion later than 33 of the 109 other live ones, and was the 288th registered.

Hepatitis B, Chronic

896 studies on the registry are indexed under Hepatitis B, Chronic; 153 are open to participants now.

Browse Hepatitis B, Chronic studies →

Open to participants now

89 of the 375 studies in Hepatitis B, Chronic with a site in China are open now. Recruiting first, the newest first:

84 more — sign in →

All 89 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 97 Hepatitis B, Chronic studies recruiting now, 33 (34%) set no upper age limit and 59 (61%) stop at 75 or younger; 11 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 375 studies in Hepatitis B, Chronic with a site in China, or all of them as a file.
02

Study summary

A multicenter, randomized, open, parallel-designed Phase II study to evaluate the efficacy and safety of HRS-5635 injection alone or in combination with other agents in patients treated for chronic hepatitis B.

03

Conditions studied

  • Chronic Hepatitis B

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Meet the standard greater than or equal to 18.5 kg/m2 and less than 35 kg/m2;
  2. Chronic defined as HBV infection documented for at least 6 months prior to screening;
  3. Virologically suppressed on nucleoside or nucleotide analogues treatment with HBV DNA below the lower limit of quantitation;
  4. On commercially available NAs monotherapy for at least 24 weeks before randomization, and the dosing regimen remained unchanged for at least 4 weeks before randomization;
  5. Need to take effective measures;
  6. Volunteer to sign an .

Exclusion criteria

Exclusion Criteria:

  1. History of cirrhosis or clinical evidence of hepatic decompensation, confirmed or suspected liver cancer, with other liver diseases other than chronic that may affect the evaluation of the study;
  2. With disease;
  3. History of solid organ transplantation or hematopoietic stem cell transplantation;
  4. and unstable or uncontrolled severe cardiovascular and cerebrovascular diseases;
  5. Malignant tumors were diagnosed within 5 years prior to randomization;
  6. Infection requiring intervention within 2 weeks prior to randomization;
  7. Major trauma or major surgery within the 12 weeks prior to randomization, or surgical plans or other treatment during the study period which the investigators determined may influence the evaluation of the study results;
  8. Laboratory tests during the screening period were obviously abnormal;
  9. Prolonged or other clinically significant abnormal results that may pose a significant safety risk to the subject during the screening period;
  10. History of drug use, alcohol or drug abuse in the 12 months prior to randomization;
  11. Participated in clinical study of other drugs (received experimental drugs);
  12. Pregnant or nursing women;
  13. Allergic to a drug ingredient or component;
  14. Other reasons for ineligibility as judged by the investigators.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
369 participants (estimated)

Study arms

  • Experimental
    HRS-5635 Injection dose 1

    Drug: HRS-5635 Injection

  • Experimental
    HRS-5635 Injection dose 2

    Drug: HRS-5635 Injection

  • Experimental
    HRS-5635 Injection dose 3

    Drug: HRS-5635 Injection

  • Experimental
    HRS-5635 Injection dose 4

    Drug: HRS-5635 Injection

  • Experimental
    HRS-5635 Injection (low dose) and Peg-IFN-α, administered by subcutaneous injection

    Drug: HRS-5635 Injection (low dose) and Peg-IFN-α

  • Experimental
    HRS-5635 Injection (high dose) and Peg-IFN-α, administered by subcutaneous injection

    Drug: HRS-5635 Injection (high dose) and Peg-IFN-α

  • Placebo comparator
    Peg-IFN-α, administered by subcutaneous injection

    Drug: Peg-IFN-α

  • Experimental
    HRS-5635 Injection with Peg-IFN-α(Part C)

    Drug: HRS-5635 Injection with Peg-IFN-α

  • Experimental
    HRS-5635 Injection(Part D)

    Drug: HRS-5635 Injection

Interventions

  • HRS-5635 Injection low dose administered by subcutaneous injection

  • HRS-5635 Injection medium dose administered by subcutaneous injection

  • HRS-5635 Injection high dose administered by subcutaneous injection

  • HRS-5635 Injection lowest dose administered by subcutaneous injection

  • DrugHRS-5635 Injection (low dose) and Peg-IFN-α

    HRS-5635 Injection (low dose) and Peg-IFN-α, administered by subcutaneous injection

  • DrugHRS-5635 Injection (high dose) and Peg-IFN-α

    HRS-5635 Injection (high dose) and Peg-IFN-α, administered by subcutaneous injection

  • DrugPeg-IFN-α

    Peg-IFN-α, administered by subcutaneous injection

  • DrugHRS-5635 Injection with Peg-IFN-α

    HRS-5635 Injection and Peg-IFN-α, administered by subcutaneous injection

  • HRS-5635 Injection, administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. PartA:Change in mean log10 serum hepatitis B surface antigen levels from baseline at week 12

    Time frame: Week 12

  2. PartB:Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48

    Time frame: Week 48

  3. PartC:Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48

    Time frame: Week 48

  4. PartD:Proportion of subjects whose serum hepatitis B surface antigen (HBsAg) had turned negative at week 48

    Time frame: Week 48

Secondary outcomes

  1. Changes from baseline in mean log10 serum hepatitis B surface antigen levels

    Time frame: Pre-specified time points up to 72 weeks

  2. Proportion of subjects with at least one log10 decline from baseline in serum hepatitis B surface antigen

    Time frame: Pre-specified time points up to 72 weeks

  3. Proportion of subjects with serum hepatitis B surface antigen loss

    Time frame: Pre-specified time points up to 72 weeks

  4. Proportion of subjects with serum hepatitis B surface antigen seroconversion

    Time frame: Pre-specified time points up to 72 weeks

  5. Proportion of subjects with hepatitis B e-antigen loss

    Time frame: Pre-specified time points up to 72 weeks

  6. Proportion of subjects with serum hepatitis B e-antigen seroconversion

    Time frame: Pre-specified time points up to 72 weeks

  7. Proportion of subjects with virologic breakthrough

    Time frame: Pre-specified time points up to 72 weeks

  8. Proportion of subjects with drug resistance

    Time frame: Pre-specified time points up to 72 weeks

  9. Proportion of subjects who meet the criteria for stopping NA therapy

    Time frame: From 48 weeks to 72 weeks

  10. Proportion of subjects with serum hepatitis B surface antigen loss and HBV DNA loss

    Time frame: Week 48

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Aug 2026, 26 months after the start.

Of 75 industry-sponsored phase 2 interventional studies under Hepatitis B, Chronic, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 39. This study's planned 26 months is above that.

Counting every sponsor, half of 87 studies reached it within 23 months; a quarter within 16 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 17, 2024
First posted
May 22, 2024
StartActual
Jun 6, 2024
Primary completionEst.
Aug 30, 2026
CompletionEst.
Jan 19, 2027
Last update
Nov 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06425341
Responsible party
Sponsor
First posted
May 22, 2024
Start date
Jun 6, 2024
Primary completion
Aug 30, 2026 (estimated)
Completion
Jan 19, 2027 (estimated)
Last update
Nov 17, 2025

Study contacts

Xiaopeng Wang
Contact
xiaopeng.wang@hengrui.com
0518-82342973

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HRS-5635

Start the discussion